Drugmakers and manufacturers in violation of the requirements will be defined under the terms as “an unlawful merchandising practice, and each package of 340B drugs affected, as defined by federal law, shall constitute a separate violation,” according to the bill’s summary.
Any company found in violation of the above will be subject to investigation, and possibly disciplinary actions from the Board of Pharmacy.
“We want to stick together, and we do believe that healthcare will be stronger if we stay together as a group and we maintain the 340B program, so it benefits all and that we don’t abuse it,” Daniel Good, vice president of pharmacy at a Mercy Health facility in Missouri told KRCU, Southeastern Missouri’s NPR station.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
